


TARGETED NANOMEDICINE FOR THE PREVENTION AND TREATMENT OF THROMBOSIS



**Thesis submitted in partial fulfillment
for the Award of Degree
Doctor of Philosophy**

By

Ms. Vishnu Priya

**Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi-221005
India**

Roll no. 18161001

Year: 2023




Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi - 221 005

CERTIFICATE

It is certified that the work contained in the thesis titled "**TARGETED NANOMEDICINE FOR THE PREVENTION AND TREATMENT OF THROMBOSIS**" by Ms. Vishnu Priya has been carried out under my supervision and that this work has been not submitted elsewhere for a degree.

It is further certified that the student has fulfilled all the requirements of Course work, Comprehensive, Candidacy, SOTA and Pre-submission seminar.


12/12/22

Dr. M.S. Muthu

Department of Pharmaceutical Engineering & Technology

Indian Institute of Technology (BHU), Varanasi

Dr. M. S. Muthu
Associate Professor
Dept. of Pharm. Engg. & Tech.
Indian Institute of Technology (BHU)
Varanasi-221005



Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi - 221 005

DECLARATION BY THE CANDIDATE

I, *Vishnu Priya*, certify that the work embodied in this Ph.D. thesis is my own bonafide work and carried out by me under the supervision of *Dr. M.S. Muthu* from *July, 2018 to May, 2023* at the *Department of Pharmaceutical Engineering & Technology*, Indian Institute of Technology (B.H.U.), Varanasi. The matter embodied in this thesis has not been submitted for the award of any other degree/diploma.

I declare that I have faithfully acknowledged and given credits to the research workers wherever their works have been cited in my work in this thesis. I further declare that I have not willfully copied any other's work, paragraphs, text, data, results, etc., reported in journals, books, magazines, reports, dissertations, theses, etc., or available at websites and have not included them in this Ph.D. thesis and have not cited as my own work.

Date: *17/5/23*

Place: *Varanasi*

(Vishnu Priya)

CERTIFICATE FROM THE SUPERVISOR

It is certified that the above statement made by the student is correct to the best of my/our knowledge.

(Dr. M.S. Muthu)
Supervisor

Dr. M. S. Muthu
Associate Professor
Dept. of Pharm. Engg. & Tech.
Indian Institute of Technology (BHU)
Varanasi-221005

(Prof. (Mrs.) Siva Hemalatha)
Head of the Department
विभागाध्यक्ष / Head

मैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग /
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय) / (BANARAS HINDU UNIVERSITY)
वाराणसी-२२१००५ / Varanasi-221005



Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi - 221 005

COPYRIGHT TRANSFER CERTIFICATE

Title of the Thesis: “TARGETED NANOMEDICINE FOR THE PREVENTION AND TREATMENT OF THROMBOSIS”

Name of the Student: Ms. VISHNU PRIYA

Copyright Transfer

The undersigned hereby assigns to the Indian Institute of Technology (B.H.U.), Varanasi all rights under copyright that may exist in and for the above thesis submitted for the award of the “*Doctor of Philosophy*”.

Date: 17/05/2023


(Vishnu Priya)

Place: Varanasi

Note: However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for author’s personal use provided that the source and the Institute’s copyright notice are indicated.

Acknowledgement

First and foremost, I want to convey my deep gratitude to "Lord Shiva" for blessing me. Every day, I thank "God" for everything that happens in my life. My greatest gratitude to Bharat Ratna Mahamana Pandit Madan Mohan Malaviya Ji, the creator of the distinguished temple of knowledge, and Prof. Mahadeva Lal Schroff, The Father of Indian Pharmaceutical Education, who lay the foundation stone of our esteemed Department of Pharmaceutics.

Despite all of your outbursts, a research supervisor is someone who always speaks well of their students. My supervisor, Dr. M.S. Muthu, taught me a lot about how to nurture a thought from an idea to a presentable work, how to present a work correctly, and how to make your pupil go through a night-out just to get a rebuttal. His guidance was invaluable throughout my research work and writing of this thesis. He gave me the freedom to work on my own time on problems that I was interested in, and he had great faith in my limited abilities. I am grateful for his intelligent observations, creative ideas, scientific acumen, critical appraisal, boundless passion, perceptive remarks, and homely working environment, which are some of the supreme traits that will be remembered as a quintessential example of outstanding mentoring.

I am indeed immensely thankful to Prof. (Mrs.) Siva Hemalatha, Head, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU) for her affection and kindly allowing me to use the facilities required to complete my research work.

I wish to express deep regards to all the distinguished and respected faculty members of the department Dr. A. K. Srivastava (Ex-Professor), Prof. Brahmeshwar Mishra, Prof. Sushil Kumar Singh, Prof. Sanjay Singh, Prof. Sushant Kumar Shrivastava, Prof. K. Sairam, Dr. Senthil Raja A., Dr. A. N. Sahu, Dr. S. K. Mishra, Dr. Ruchi Chawla, Dr. Ashok k. Maurya, Dr. Prasanta. K. Nayak, Dr. G. P. Modi, Dr. Shreyans. K. Jain, Dr. Vinod Tiwari, Dr. Ashish.

K. Agrawal, Dr. Rajnish, Dr. Deepak Kamar, Dr. Dinesh Kumar and Dr. Jairam Meena for their kind cooperation at all moments during the progress of my research. I am thankful to Dr. Sanjeev K. Singh, Department of Physiology, IMS, Banaras Hindu University and his lab members Revand Ravindran and Puneet Baseer for helping me during my in vivo studies. I express my gratitude to Dr. Sanjeev Kumar Mahto, School of Biomedical Engineering & Technology, IIT BHU, for kindly providing cell culture facilities. I am very much grateful to Dr. Dharmendra Jain, Department of Cardiology, IMS, Banaras Hindu University for providing the necessary clinical samples. I also acknowledge Dr. Sandip Kumar, Department of Pathology, IMS, Banaras Hindu University for helping me in clotting studies.

I owe my respect to all the non-teaching staff of the department, especially Mr. Nand Lal, Mr. Virendra Kumar, Mr. Akhila Nand Upadhyay, Mr. Atul Kumar Gupta, Mr. Yashwant Singh, Mr. Anand Kumar and Mr. Surya Pratap Singh for their support and help. I would like to express my gratitude to the Ministry of Education, Government of India, for giving me financial assistance in a teaching assistantship, which has greatly aided in achieving my research objectives.

I am grateful to my friendly lab mates Mr. Matte Kasi Viswanadh, Mr. Vikas, Mr. Abhishesh Kumar Mehata, Dr. Chandra Sekhar Singh, Ms. Ankita Sanjay Burande, Mr. Sheik Azad, Ms. Nishi Agrawal, Susanta Kumar Rout, Mr. Ankit Malik, Mrs. Nikita, Mr. Gokul, Mr. Aseem Setia, Mr. Piyush Dhamija, Jyoti Bonlawar and Miss Samridhi. They built a cheerful and fun-filled working environment and cultivated camaraderie within the laboratory, and they are like my extended family, always willing to support me in any way imaginable. I am deeply indebted and thankful to my dear friends Mr. Kancharla Bhanukiran, Mr. Bharat Goel, Miss. Deepa Dehari who always ready to extend help and from whom I comprehended many

research-related aspects. I remain thankful to all those who have been directly or indirectly helped and related to my project work.

I am also grateful to all of my family members, especially my father Mr. Mahendra Prasad, mother Srimati Anju Kumari, and sisters Dr. Shubh Lakshmi & Miss. Shrishti Shiva, who have always supported me throughout my life, allowing me to make my own decisions and helping me grow into the person I am today.

Place: Varanasi

Date: 17-05-2023

A handwritten signature in black ink, enclosed within a circular scribble. The signature appears to be 'Vishnu Priya'.

(Vishnu Priya)

CONTENTS

List of tables

List of figures

Abbreviations

Preface

Chapters	Page No.
1. Introduction.....	1-16
2. Literature review.....	17-65
2.1. Molecular targets available for antithrombotic nanomedicine.....	17-21
2.2. Nanoplatfoms developed for anti-thrombotic therapy.....	21-22
2.2.1. Liposomes	22-24
2.2.2. Micelles	24-25
2.2.3. Polymeric nanoparticles	25
2.2.4. Material-based nanoparticles (inorganic nanoparticles)	25-26
2.2.5. Other biological vectors.....	26-27
2.3. Strategies involved in nanocarrier based thrombus targeting	27-29
2.3.1. Passive targeted antithrombotic nanotherapeutics	30
2.3.1.1. Shear activated nanotherapeutics.....	30-31
2.3.1.2. Stimulus-sensitive antithrombotic nanomedicines.....	31-33
2.3.2. Active targeted antithrombotic nanotherapeutics.....	34
2.3.2.1. Ligand-based thrombus targeted nanomedicines.....	34-40
2.3.3. Miscellaneous strategies involved in thrombus targeted nanomedicine.....	40
2.3.3.1. Sonothrombolysis	40-42
2.3.3.2. Magneto-thrombolysis.....	42-45
2.3.3.3. Dual targeted antithrombotic nanomedicines.....	45-46
2.4. Antithrombotic nanomedicine for theranostics applications	47-50
2.5. Mesoporous silica nanoparticle (MSN).....	50-51
2.5.1. Methods of preparation of mesoporous silica nanoparticle.....	52
2.5.1.1. Sol-gel method.....	52
2.5.1.2. Template assisted method.....	52
2.5.1.3. Chemical etching method.....	53
2.5.1.4. Microwave assisted method.....	53
2.5.2. Biosimilar's profile	54
2.5.2.1. Chemical structure.....	54
2.5.2.2. Description.....	54
2.5.2.3. Molecular weight.....	54
2.5.2.4. Molecular formula.....	54
2.5.2.5. Half-life.....	54

2.5.2.6.Mechanism of action.....	54
2.5.2.7.Indication.....	54
2.5.2.8.Side effects.....	55
2.5.3. Tetraethyl orthosilicate	55
2.5.3.1.Chemical structure.....	55
2.5.3.2.Description.....	55
2.5.3.3.IUPAC name.....	55
2.5.3.4.Molecular formula.....	55
2.5.3.5.Molecular weight.....	55
2.5.3.6.Physical properties.....	55
2.5.3.7.Metabolism.....	56
2.5.3.8.Uses.....	56
2.5.4. Cetyltrimethyl ammonium bromide	56
2.5.4.1.Chemical structure.....	56
2.5.4.2.Description.....	56
2.5.4.3.IUPAC name.....	56
2.5.4.4.Molecular formula.....	56
2.5.4.5.Molecular weight.....	56
2.5.4.6.Physical properties.....	56
2.5.4.7.Uses.....	56
2.5.5. (3-Aminopropyl) triethoxysilane	57
2.5.5.1.Chemical structure.....	57
2.5.5.2.Description.....	57
2.5.5.3.IUPAC name.....	57
2.5.5.4.Molecular formula.....	57
2.5.5.5.Molecular weight.....	57
2.5.5.6.Physical properties.....	57
2.5.5.7.Uses.....	57
2.6. Liposomes	57-58
2.6.1. Methods of preparation of liposomes	58
2.6.1.1.Thin film hydration method.....	58-59
2.6.1.2.Detergent removal method.....	59
2.6.1.3.Solvent injection method.....	59
2.6.1.3.1. Ethanol injection method.....	59
2.6.1.3.2. Ether injection method.....	60
2.6.1.4.Reverse phase evaporation method.....	60
2.6.1.5.Sonication method.....	60-61
2.6.1.6.Extrusion method.....	61
2.6.1.7.Homogenization.....	61-62
2.6.1.8. Novel methodologies.....	62
2.6.2. Drug profile	62
2.6.2.1. Chemical structure.....	62
2.6.2.2. Description.....	62-63
2.6.2.3. IUPAC name.....	63
2.6.2.4. Molecular formula.....	63
2.6.2.5. Molecular weight.....	63

2.6.2.6. Elimination half-life.....	63
2.6.2.7. Solubility.....	63
2.6.3. Cholesterol.....	63
2.6.3.1. Chemical structure.....	63
2.6.3.2. Description.....	63
2.6.3.3. IUPAC name.....	63
2.6.3.4. Molecular formula.....	63
2.6.3.5. Molecular weight.....	64
2.6.3.6. Physical properties.....	64
2.6.3.7. Solubility.....	64
2.6.3.8. Metabolism.....	64
2.6.4. Tocopheryl polyethylene glycol succinate	64
2.6.4.1. Chemical structure.....	64
2.6.4.2. Description.....	64
2.6.4.3. IUPAC name.....	65
2.6.4.4. Molecular formula.....	65
2.6.4.5. Molecular weight.....	65
2.6.5. Phosphatidylcholine	65
2.6.5.1. Chemical structure.....	65
2.6.5.2. Description.....	65
2.6.5.3. Molecular formula.....	65
2.6.5.4. Molecular weight.....	65
2.6.5.5. Physical properties.....	65
3. Formulation and optimization of abciximab coated mesoporous silica nanoparticles for improved antithrombotic activity.....	66-100
3.1. Objective.....	66
3.2. Plan of study.....	66-67
3.3. Material.....	67
3.4. Methods.....	67
3.4.1. Selection of CMAs and CQAs.....	67
3.4.1.1. Formulation optimization by Box-Behnken Design	68
3.4.2. Preparation of amino-functionalized MSN	68-69
3.4.3. Conjugation of ABX to MSN- NH ₂	69
3.4.4. Preparation of DiD dye loaded ABX coated MSN-NH ₂	69-70
3.4.5. Nanoparticle characterizations	71
3.4.5.1. Particle size, polydispersity and zeta potential.....	71
3.4.5.2. Transmission electron microscopy (TEM) analysis.....	71
3.4.5.3. Scanning electron microscopy (SEM) analysis.....	72
3.4.5.4. Surface chemistry	72
3.4.5.5. X-ray photoelectron spectroscopy (XPS) analysis.....	72
3.4.5.6. Thermogravimetric analysis (TGA).....	72-73
3.4.5.7. Degree of ABX conjugation.....	73
3.4.5.8. <i>In-vitro</i> characterization.....	73
3.4.5.8.1. <i>In-vitro</i> ABX release	73
3.4.5.8.2. <i>In-vitro</i> blood clot assay	74
3.4.5.9. <i>In-vitro</i> clot targeting efficiency.....	75

3.4.5.9.1. <i>In-vitro</i> platelet binding assay.....	75
3.4.5.9.2. Image-J analysis of confocal laser microscopic images.....	76
3.4.5.10. <i>In-vitro</i> safety assessment	77
3.4.5.10.1. Blood Smear.....	77
3.4.5.10.2. Hemolytic Assay.....	78-79
3.4.5.11. <i>In vivo</i> studies	79
3.4.5.11.1. Tail bleeding assay	79-80
3.4.5.11.2. Blood clotting time study.....	80
3.4.5.11.3. <i>In-vivo</i> FeCl ₃ induced model for thrombus formation by B.P. measurement.....	81-82
3.4.5.12. Statistical analysis.....	82
3.5. Results and discussion.....	84
3.5.1. Formulation optimization by Box-Behnken Design.....	84
3.5.1.1 Effect on particle size	84-85
3.5.1.2. Effect on PDI.....	85-86
3.5.2. Nanoparticles characterization	86
3.5.2.1. Size, polydispersity, and zeta potential of nanoparticles	86-87
3.5.2.2. TEM analysis	87
3.5.2.3. Scanning electron microscopy	87-88
3.5.2.4. Surface chemistry.....	88-89
3.5.2.5. XRD analysis.....	89
3.5.2.6. TGA study.....	89
3.5.2.7. Degree of ABX conjugation.....	90
3.5.2.8. <i>In-vitro</i> analysis	91
3.5.2.8.1. <i>In-vitro</i> ABX release	91
3.5.2.8.1. Blood clot assay	91
3.5.2.9. <i>In-vitro</i> clot targeting efficiency.....	92
3.5.2.9.1. <i>In-vitro</i> platelet binding assay	92-93
3.5.2.9.2. Image-J analysis of CLSM images.....	93
3.5.2.10 <i>In-vitro</i> safety assessment.....	94
3.5.2.10.1. Blood Smear.....	94
3.5.2.10.2. Hemolytic Assay.....	95
3.5.2.11. <i>In-vivo</i> studies.....	96
3.5.2.11.1. Tail bleeding assay.....	96
3.5.2.11.2. Blood clotting time study.....	96
3.5.2.11.3. <i>In-vivo</i> FeCl ₃ induced model for thrombus formation by B.P. measurement.....	97
3.6. Conclusion.....	98-100
4. GPIIb/IIIa receptor targeted rutin loaded liposomes for site-specific antithrombotic effect	101-148
4.1. Objective.....	101
4.2 Plan of study.....	101-102
4.3. Material.....	102
4.4. Methods.....	103
4.4.1. Selection of CMAs and CQAs.....	103

4.4.1.1. Formulation optimization by Box-Behnken design	103
4.4.2. Fabrication of nontargeted and targeted liposomes	104-105
4.4.3. Preparation of dye loaded liposomes.....	106
4.4.4. Evaluation of physicochemical characteristics.....	106
4.4.2.1. Particle size and polydispersity index (PI) determination .	106
4.4.2.2. ζ potential measurement	107
4.4.4.3. Encapsulation Efficiency.....	107
4.4.4.4. Scanning electron microscopy (SEM).....	107
4.4.4.5. Transmission electron microscopy (TEM).....	107-108
4.4.4.6. Degree of peptide conjugation.....	108
4.4.4.7. Surface chemistry.....	108
4.4.4.8. X-ray diffraction (XRD) analysis.....	108-109
4.4.4.9. Thermogravimetric analysis (TGA).....	109
4.4.5. <i>In-vitro</i> studies.....	109
4.4.5.1. <i>In-vitro</i> drug release study.....	109
4.4.5.2. Blood clot analysis.....	110
4.4.5.3. <i>In-vitro</i> coagulation aPTT and PT assay.....	110
4.4.5.4. Platelet aggregation study.....	111-112
4.4.5.5. Biocompatibility and safety evaluation.....	112
4.4.5.5.1. Blood smear analysis.....	112
4.4.5.5.2. Hemolytic assay.....	113
4.4.5.6. <i>In-vitro</i> cytotoxicity assay.....	113-114
4.4.5.7. <i>In-vitro</i> clot targeting efficiency by platelet binding.....	114
4.4.5.7.1. <i>In-vitro</i> imaging.....	114
4.4.5.7.2. ImageJ analysis of CLSM images.....	115
4.4.5.8. Stability studies.....	115
4.4.5.8.1. Stability study in serum.....	115
4.4.5.8.2. Storage stability study.....	115
4.4.6. <i>In-vivo</i> studies.....	115
4.4.6.1. Tail bleeding assay.....	115-116
4.4.6.2. Blood clotting time study.....	116
4.4.6.3. <i>In-vivo</i> FeCl ₃ model for thrombus formation by B.P measurement.....	116-117
4.4.6.4. Pharmacokinetics study.....	117-118
4.4.6.5. Toxicity assay.....	118
4.4.7. Statistical investigations.....	118-119
4.5. Results and discussion.....	119
4.5.1. Formulation optimization by Box-Behnken design.....	119
4.5.1.1. Effect on particle size.....	119-120
4.5.1.2. Effect on PDI.....	120-121
4.5.1.3. Effect on %EE.....	121-122
4.5.2. Evaluation of physicochemical characteristics.....	123
4.5.2.1. Particle size, PI, and ζ potential determination.....	123
4.5.2.2. Encapsulation efficiency.....	123-124
4.5.2.3. SEM and TEM	124-125
4.5.2.4. Bradford assay.....	125-126

4.5.2.5. Surface chemistry.....	126-127
4.5.2.6. XRD studies.....	127-128
4.5.2.7. TGA studies.....	128-129
4.5.3. <i>In-vitro</i> studies.....	129
4.5.3.1. <i>In-vitro</i> drug release study.....	129-130
4.5.3.2. Blood clot analysis	130-131
4.5.3.3. <i>In-vitro</i> coagulation aPTT and PT assay.....	131-132
4.5.3.4. Platelet aggregation studies.....	132-133
4.5.3.5. Biocompatibility and safety evaluation.....	133
4.5.3.5.1. Blood Smear.....	133-134
4.5.3.5.2. Hemolytic Assay.....	134-135
4.5.3.6. <i>In-vitro</i> cytotoxicity assay.....	135-136
4.5.3.7. <i>In-vitro</i> clot targeting efficiency by platelet binding...	137
4.5.3.7.1. <i>In-vitro</i> imaging.....	137
4.5.3.7.2. Image-J analysis of CLSM images.....	137-138
4.5.3.8. Stability study.....	139
4.5.3.8.1. Serum stability study.....	139
4.5.3.8.2. Storage stability study.....	139-140
4.5.4. <i>In-vivo</i> studies.....	140
4.5.4.1. Tail bleeding assay.....	140-141
4.5.4.2. Blood clotting time study.....	141
4.5.4.3. FeCl ₃ model for thrombus formation by B.P. measurement.....	141-144
4.5.4.4. Pharmacokinetic study.....	144-146
4.5.4.5. Toxicity assay.....	146-147
4.6. Conclusion.....	147-148
5. Summary and conclusions.....	149-155
6. References.....	156-185
7. Publications.....	186-187
8. Curriculum Vitae.....	188-193

List of Figures

Figure No.	Description	Page No.
1.1	Mechanism of the primary hemostasis and secondary hemostasis	4
2.1	Molecular targets of thrombus and the available drugs for targeting. (A) Molecular targets available at the thrombus site during hemostasis and (B) drugs used to control thrombosis: targets of different antithrombotic drugs	21
2.2	Anti-thrombotic nanomedicine and their mechanism of action. (A) Nanocarriers for targeted anti-thrombotic drug delivery (i) liposomes (ii) micelles (iii) biological vectors (iv) polymeric nanoparticle (v) material based (silica) nanoparticle, (B) working principle of targeted thrombolysis. (i) thrombus remains with saline treatment, (ii) nanoformulation binding to local thrombus site helps to reduce clot formation, (iii) targeted nanomedicine works more potently and dissolves the clot	29
2.3	Different strategies of nanocarrier based thrombus targeting. (A) ligand based targeting with peptide conjugated nanoparticles, (B) irradiation based targeting approach by applied mechanical force (a) ultrasound based targeting with echogenic nanoparticles (b) magnetic field based thrombus targeting with magnetic nanoparticles (C) targeting by the high shear rate exists at the thrombus site	47
2.4	Surface functionality of MSNs	51
3.1	Graphical illustration of preparation method of functionalized MSN. (A) synthesis of MSN-NH ₂ (B) ABX functionalization of MSN-NH ₂ by ionic interaction	70
3.2	<i>In-vitro</i> drug release by sample separation technique	74
3.3	<i>In-vitro</i> drug blood clot assay	74

3.4	Graphical illustration of <i>in-vitro</i> imaging by photon imager optima	76
3.5	Graphical representation of <i>in-vitro</i> imaging by CLSM	77
3.6	Schematic representation of blood smear preparation and analysis	78
3.7	Schematic illustration of method of hemolysis study	79
3.8	Pictorial representation of method of tail bleeding assay	80
3.9	Graphical representation of method of <i>in-vivo</i> clotting time study	81
3.10	A) Surgical steps of FeCl ₃ model B) Data recording setup for FeCl ₃ model in rat	83
3.11	The 2D contour plots and 3D surface plots showing the effect of independent variables on particle size	85
3.12	The 2D contour plots and 3D surface plots showing the effect of independent variables on PDI	86
3.13	A) TEM, images of MSN-NH ₂ and MSN-ABX B) SEM image of MSN-NH ₂	88
3.14	(A) XPS survey of MSN-NH ₂ and MSN-ABX. B) XRD spectra of MSN-NH ₂ C) SAED pattern of MSN-NH ₂ D) TGA pattern of MSN-NH ₂	90
3.15	(A) Graphical representation of <i>in-vitro</i> drug release study of prepared MSN-ABX (solid orange line) as compared to ABX inj. (solid pink line). (B) Positive saline control, MSN-NH ₂ , MSN-ABX, and negative control (ABX) were incubated with freshly collected human blood. <i>In-vitro</i> antithrombotic effect of prepared formulation in terms of weight of formed blood clot has been presented. Each of the value was presented in mean ± S.D of three independent investigations. A significant (P<0.05) change in clot formation has been observed	92
3.16	(A) Confocal laser scanning microscopic images and binary black and white images (converted by the image-J software) of activated platelets treated with DiD dye, DiD-MSN-NH ₂ and DiD-MSN-	94

ABX. (A.1) The percentage fluorescent intensity of red channels presents in their corresponding microscopic images. (B) Fluorescent images of vials containing standard DiD dye solution and washed activated platelets after the treatment with DiD dye control, saline, DiD-MSN-NH₂ and DiD-MSN-ABX obtained by photon imager optima imaging system. (B.1) Bar graph demonstrating the % interaction of DiD-MSN-NH₂ and DiD-MSN-ABX as compared to DiD control

3.17	(A) Bar graph showing % hemolysis and (B) bright microscopic images (10 X) of human blood treated with ABX injection, MSN-NH ₂ and MSN-ABX.	95
3.18	Bar graph depicting the A) bleeding time B) clotting time in sec.	97
3.19	A) Line graph showing the original B.P. measurements B) Bar diagram represents the time of 50% fall in BP in CA (ns ($p \geq 0.05$), * ($p < 0.05$), ** ($p < 0.01$), and *** ($p < 0.001$))	98
3.20	Graphical illustration of ABX coated MSN for antithrombotic therapy	100
4.1	(A) Schematic representation of synthesis of RUT-LIPO (B) Scheme of RGD or ABX conjugation on RUT-LIPO.	105
4.2	Graphical representation of drug release study by dialysis bag method	109
4.3	Graphical representation of method for PT and aPTT assay	111
4.4	Graphical representation of method for platelet aggregation study	112
4.5	The 2D contour plots and 3D surface plots showing the effect of independent variables on particle size	120
4.6	The 2D contour plots and 3D surface plots showing the effect of independent variables on PDI	121
4.7	The 2D contour plots and 3D surface plots showing the effect of independent variables on %EE	122

4.8	A) SEM images, B) TEM images, C) SAED pattern of RUT-LIPO, RGD-RUT-LIPO and ABX-RUT-LIPO	125
4.9	A) XPS survey of RUT-LIPO, RGD-RUT-LIPO and ABX- RUT-LIPO B) Bar graph of N1s atomic percentage in XPS spectra	127
4.10	A) XRD spectra overlay of RUT, non-targeted and targeted liposomes B) TGA spectra of cholesterol, HSPC, RUT, TPGS, and RUT-LIPO.	129
4.11	A) <i>In-vitro</i> drug release study of RUT and liposomes B) Bar graph representing %blood clot formation. C) Blood clot assay of non-targeted and targeted liposomes	131
4.12	A) <i>In-vitro</i> PT in terms of time in sec has been presented B) In-vitro aPTT in terms of time in second has been presented for non-targeted and targeted liposomes, with saline as a positive control and RUT as a negative control. C) A plot of platelet aggregation study for the RUT, non-targeted and targeted liposomes	133
4.13	A) Bright microscopic images (10 X) and B) Percent hemolysis of human blood treated with saline, RUT, non-targeted, and targeted liposomes	135
4.14	Cell cytotoxicity study of liposomal formulations in L929 fibroblast cell line	136
4.15	A) Bioluminescent images of vials containing activated platelets after the incubation with saline, DiD dye, non-targeted and targeted formulations. A.1) Graphical illustration of % interaction of non-targeted and targeted liposomes in comparison with DiD control; B) Fluorescent images and converted binary black and white images of activated platelets after treatment with DiD dye, non-targeted and targeted liposomes. B.1) Graphical representation of the % fluorescent intensity of red channels from CLSM images	138
4.16	Stability study: size distribution of RUT-LIPO in 10% fetal bovine Serum	139
4.17	A) Tail bleeding assay in mice B) red intensity of blood of saline, BLN-RGD-LIPO, BLN-ABX-LIPO, RUT solution, non-targeted, RGD targeted, and ABX-targeted liposomes after tail bleeding C)	143

Bar graph representing bleeding time in s. D) Bar graph depicting the clotting time in s. E) Line graph showing the original B.P. measurements F) Effect of various liposomal formulations on FeCl₃ induced blockage in CA blood flow. Bar diagram represents the time of 50% fall in B.P. of CA.

- 4.18** Chromatograms of analytical method development of rutin **145**
- 4.19** *In-vivo* pharmacokinetic study of RUT, RUT-LIPO, RGD-RUT-LIPO, ABX-RUT-LIPO after i.v. administration **146**
- 4.20** Histopathological examination of rat kidney, heart, brain, liver (H&E staining magnification 10X) after administration of saline, RUT, non-targeted, and targeted liposomes. **147**

List of Tables

Table No.	Description	Page No.
1.1	Utilization of drug loaded nanocarriers to solve risk associated with anti-thrombotic therapy	12
2.1	Molecular targets currently being studied for nanotherapeutics in the prophylaxis and treatment of thrombosis	20
2.2	Different approaches to thrombus targeting by external mechanical force or by passive targeting	32-33
2.3	Peptide conjugated targeted nanocarriers for delivery of anti-thrombotic drugs	37-40
3.1	Box-Behnken design of MSN explaining different variables by Design Expert version 11 (Trial)	68
3.2	Formula of non-targeted and ABX decorated MSN	71
3.3	Box-Behnken design table with the response values	84
3.4	Particle size, polydispersity, surface charge and entrapment efficiency values of MSN-NH ₂ and MSN-ABX	87
3.5	Effect of various formulations on blood pressure in FeCl ₃ induced blockage in CA	97
4.1	Box-Behnken design of liposomes explaining different variables	103-104
4.2	Composition formulas of liposomal preparations	106
4.3	Box-Behnken design table with the response values	119
4.4	Particle size, PI, zeta potential and % EE data of different liposomal formulations	124
4.5	Stability of liposomes after and before 3 months of storage at 4-8°C in terms of size and PDI	140
4.6	Effect of various formulations on blood pressure in FeCl ₃ induced blockage in CA	144
4.7	Pharmacokinetic parameters of RUT, RUT-LIPO, RGD-RUT-LIPO, and ABX-RUT-LIPO after i.v. administration at 5 mg/kg.	146

List of Abbreviations and Symbols

%	Percentage
°C	Temperature on the Celsius scale
CVDs	Cardiovascular diseases
RBCs	Red blood cells
SLE	Systemic lupus erythematosus
HITT	Heparin-induced thrombocytopenia and thrombosis
t-PA	Tissue plasminogen activator
PAR	Protease-Activated Receptor
ABX	Abciximab
RUT	Rutin
MSNs	Mesoporous silica nanoparticles
RGD	Arginylglycylaspartic acid
US	Ultrasound
CA	Carotid artery
PDI	Polydispersity index
ANOVA	Analysis of variance
AUC	Area under the curve
C _{max}	Maximum plasma concentration
DMEM	Dulbecco's Modified Eagle Medium
DLS	Dynamic light scattering
EDC	1-ethyl-3-(3-dimethylaminopropyl)-N-carbodiimide hydrochloride
EE	Entrapment efficiency
FBS	Fetal bovine serum
USFDA	United States Food and Drug Administration
h	Hour (s)
HPLC	High-performance liquid chromatography
IC ₅₀	Half-maximal inhibitory concentration
<i>i.v.</i>	Intravenous
kDa	Kilodalton
mV	Milli volts

mg	Milligram
min	Minute
mL	Milliliter
MRT	Mean residence time
NaOH	Sodium hydroxide
NHS	N-hydroxy-succinimide
nm	Nanometer
NP/NPs	Nanoparticles
PBS	Phosphate buffered saline
PDI	Polydispersity index
rpm	Revolutions per minute
S.D.	Standard deviation
sec	Seconds
SEM	Scanning electron microscopy
T _{max}	Time to reach maximum plasma concentration
T ₅₀	Time required for 50% drug release
TEM	Transmission electron microscopy
TPGS	D- α -tocopheryl polyethylene glycol 1000 succinate
TPGS-COOH	Acid functionalized TPGS
μ g	Microgram
μ l	Microliter
μ M	Micromole
XPS	X-ray photoelectron spectroscopy
XRD	X-ray diffraction spectroscopy
RES	Reticuloendothelial system
PEG	Polyethylene glycol

Preface

Ischemic cardiovascular diseases are one of the leading reasons for morbidity as well as mortality in the 21st century. The formation of thrombi in blood vessels due to the disruption of atherosclerotic plaques is considered as the major reason that triggers their onset. Thrombosis plays a pivotal role in the creation of various cardiovascular events, such as ischemic cardiovascular disease and venous thromboembolism. Thrombosis is defined as localized blood clotting regulated by an activated coagulation cascade due to a myriad of abnormal physiological conditions. In other words, this disease mainly occurs due to the deposition of blood clots in vessels (thrombus) that obstruct blood flow in the circulatory system. A thrombus is an end product of the hemostatic process, resulting from aggregated platelet plugs and activated clotting factors involved in the coagulation pathway. It plays a dual role; physiological in the case of vascular damage and pathological in the case of thrombotic events. Currently, for the treatment of thrombosis, rapid revascularization is available as the best emergent therapy, by angioplasty and surgical interventions of the occluded vessel. But it is a time taking process involving the transfer of the patient to a specialized hospital where cardiac surgery can be performed. Clinically, intravenous and oral administration of various anti-thrombotic drugs like anticoagulants, anti-platelets, and thrombolytic agents is also a treatment option for arterial and venous thrombosis for cardiac patients. Many of these anti-thrombotic drugs have short half-lives, require high doses, have poor targeting capability, have low therapeutic windows, require constant monitoring, and can easily induce hemorrhage and other side effects. Therefore, effective and safe delivery of these anti-thrombotic agents at the target site is the primary objective of anti-thrombotic treatment. Hence, in order to minimize side effects and maximize targeting efficiency, various approaches have been exploited, such as formulating drug-loaded nanoparticles, liposomes, micelles, nano-vectors, etc. with the addition of targeting

peptides on their surface or by using different external forces like a magnetic field, ultrasound, heat, light, etc.

The present study includes the development of mesoporous silica nanoparticles (MSN) for the efficient delivery of abciximab (ABX) for targeted and improved antithrombotic activity and targeted rutin-loaded liposomes for site-specific antithrombotic effects. The prepared nanoformulations were characterized through a variety of characterization parameters, including particle size, zeta potential, percent entrapment efficiency, morphological characterization (scanning electron microscopy, and transmission electron microscopy) encapsulation, drug release, hemolysis, targeting capability, platelet binding fluorescence imaging study, hemolysis, clot lysis, blood clot assay, tail bleeding, clotting time, ferric chloride-induced thrombosis study, pharmacokinetic study, and histopathological study.

Firstly, ABX decorated MSN was synthesized and the physicochemical characterization confirms the successful loading of ABX by X-ray photoelectron spectroscopy, transmission electron microscopy, and Bradford assay. Activity based analysis suggest the therapeutic effect of ABX remains same after conjugation. *In-vitro* imaging study suggest the potent affinity of MSN-ABX towards activated platelets. *In-vivo* analysis demonstrated the enhancement of therapeutic effect with no bleeding risk over clinical ABX injection. Furthermore, biosafety evaluations presented its *in-vitro* safety in human blood.

Moreover, we proposed novel liposomal formulation, which was loaded with RUT, and the surface of these vesicles was conjugated with tripeptide RGD and ABX (monoclonal antibody) as a targeting moiety (antagonist of GPIIb/IIIa receptor) to target the thrombus site were characterized for their physicochemical properties confirms satisfiable data related to size, shape, zeta potential, crystallinity, thermal stability and surface chemistry.

The non-targeted and targeted liposomal formulations showed good stability, satisfiable

hemocompatibility, better *in-vitro* and *in-vivo* efficacy as compared to pure drug. In comparison with RUT, RUT-LIPO solved the solubility, bioavailability, and short half-life problem of RUT, but minimized related side effects as well. Moreover, an *in-vitro* assessment carried out with human blood showed the more credible antithrombotic potential of ABX-RUT-LIPO over RGD-RUT-LIPO due to its crucial binding to human integrin receptors. *In-vivo* evaluations demonstrated that RUT-LIPO, RGD-RUT-LIPO, and ABX-RUT-LIPO liposomal formulations maintained the antithrombotic function of RUT, prolonged the coagulation time in both intrinsic and extrinsic pathways. The histopathological examination demonstrated better safety in Sprague Dawley rats as compared to RUT.